Visiting Scientist

Research Group Home Page: 

Work address: 
Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE

A Phase I study of pegylated arginine deiminase (pegargiminase), cisplatin and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma.

E-pub date: 31 Jan 2019

Enhanced detection of circulating tumor DNA by fragment size analysis.

E-pub date: 31 Oct 2018

Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.

E-pub date: 31 Oct 2018

Correction: A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors.

E-pub date: 31 Oct 2018

A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo.

E-pub date: 01 Jan 2018

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

E-pub date: 01 Jun 2017

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

E-pub date: 01 Apr 2017

The role of chemotherapy and new targeted agents in the management of primary prostate cancer.

E-pub date: 31 Dec 2016

Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma.

E-pub date: 26 Apr 2016

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.

E-pub date: 01 Sep 2015

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

E-pub date: 01 Apr 2015

A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.

E-pub date: 31 Aug 2014

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

E-pub date: 15 Aug 2014

A 46 year old man with carcinoma of unknown primary site.

E-pub date: 31 Jul 2012

Another patient with low back pain.

E-pub date: 31 May 2012

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.

E-pub date: 01 Feb 2012

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.

E-pub date: 01 Jun 2011

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.

E-pub date: 15 Mar 2011

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.

E-pub date: 15 Jul 2010

Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.

E-pub date: 01 Mar 2009

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.

E-pub date: 15 Oct 2008

Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development.

E-pub date: 31 Oct 2007

Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

E-pub date: 15 Oct 2007

Inhibition of neuronal high voltage-activated calcium channels by insect peptides: a comparison with the actions of omega-conotoxin GVIA.

E-pub date: 01 Feb 1997

Show all